anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, immuno-analytical assays will be developed for determining the titres of malaria antibodies in sera of two groups (malaria patients and donors/healthy volunteers) using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens. Individuals in the two groups presenting to Shai-Osudoku District hospital will be screened for signs and symptoms of malaria according to the WHO criteria. Those within the inclusion and exclusion criteria will be introduced to the study through informed consent for adults (18 years and over) or parents/guardians for children below 12 years and assent for adolescents between 12 and below 18 years, along with informed consent from their parents. Enrolled study participants' demographic data and vital signs will be captured electronically onto the CRF. Patients will have their clinical history and detailed physical examination done by the study clinicians and then be sent to the laboratory for investigations to confirm the malaria diagnosis. The results of patients will be communicated to the study clinician to commence the appropriate treatment. At the of the study, the results of all assays will be analyzed to determine if this test can be used to diagnose malaria infection.
Background and Objectives: The goal of this study was to assess the impact of supplementation with a combination of nutrients on metabolic-dysfunction-associated steatotic liver disease (MASLD)-related liver parameters, and other parameters related to metabolic syndrome in adults with obesity. These measurements included anthropometric and lipid profiling, and FibroScan technology (controlled attenuation parameter (CAP) and transient elastography (TE) values). Materials and Methods: A double-blind, placebo-controlled pilot clinical trial was conducted over a three-month treatment period. Adults with metabolic syndrome and obesity were allocated to receive either a cocktail of nutrients with defined daily dosages (5-MTHF, betaine, alpha-linolenic acid, eicosapentaenoic acid, choline bitartrate, docosahexaenoic acid, and vitamin B12) or a placebo. The participants were evaluated at the start and the end of the three-month treatment period. Results: A total of 155 participants entered the study, comprising 84 in the treatment group and 71 in the placebo group. The administration of the nutritional supplement resulted in a notable reduction in both CAP and TE scores when compared to the placebo group. The treatment group exhibited a mean reduction in CAP of 4% (p < 0.05) and a mean reduction in TE of 7.8% (p < 0.05), indicative of a decline in liver fat content and fibrosis. Conclusions: The supplementation over a period of three months led to a significant amelioration of liver fibrosis and steatosis parameters in adults with metabolic syndrome and obesity. These findings suggest that this supplementation regimen could be a beneficial adjunct therapy for improving liver health in adults with obesity-induced MASLD.
Pancreatic cancer is often diagnosed at an advanced stage and is frequently associated with severe pain. Traditional pain management in this condition may be improved with the use of topical diclofenac. A 39-year-old man with advanced pancreatic fibrosarcoma metastatic to the thoracic spine presented to the hospital with severe abdominal pain refractory to escalating doses of opioids. A celiac plexus block produced significant, yet inadequate, pain reduction. Satisfactory pain control and opioid de-escalation were ultimately achieved with the application of topical diclofenac gel to an area of bony metastasis. This case illustrates the potential for pain control using topical diclofenac in patients with pancreatic soft tissue tumors and vertebral metastases. Topical diclofenac may exert antitumoral effects and targeted application may improve absorption, leading to improved pain control. The use of topical diclofenac for pain management in metastatic pancreatic cancer presents an interesting tool that should be considered in similar cases.
The invention discloses the compounds, pharmaceutical compositions containing such compounds and methods for obtaining and using the given compounds. 	The described compounds are amides which can be prepared from certain heteroarylcontaining carboxylic acids and certain diazabicycloalcanes. 	The given compounds exhibit selectivity for neuronal nicotinic receptors the α4β2 subtype in the central nervous system (CNS) and are bound with them with high affinity. 	The described compounds and compositions can be used to treat and/or prevent a wide variety of diseases and disorders, particular disorders of the CNS. 	The compound can: (i) change the number of nicotinic cholinergic receptors in the brain of the patient; (ii) exhibit neuroprotective effect and (iii) when used in effective amounts, not result in perceptible harmful side effects (e.g. the side effects such as significant rise in blood pressure and heart rate, significant negative effect on the gastrointestinal tract, and significant effect on skeletal muscles).
Particulate matter 2.5 (PM2.5) pollution has emerged as a major global public health concern because of its adverse effects on human health. Our group has previously demonstrated that PM2.5 exposure can seriously impair ovarian function. However, the underlying mechanisms remain a mystery. This study verifies ovarian damage in mice, evidenced by inflammatory cell infiltration and follicular atresia, following 5 months of PM2.5 exposure via tracheal drip (35 µg/m³ for low dose and 150 µg/m³ for high dose). In addition, PM2.5 exposure inhibited the cell viability of human granulosa cells (KGN) and induced apoptosis at the concentrations of 50, 100, and 150 µg/mL for 24 h. The apoptosis of KGN cells induced by inflammation contributes to follicular atresia. Furthermore, we conducted RNA-sequencing analysis to identify the genes and pathways triggered by PM2.5 (100 µg/mL) exposure, which decreases the KGN cell viability. We found a significant increase in Activating Transcription Factor 3 (ATF3). Further mechanistic studies reveal a strong association between PM2.5-induced apoptosis, inflammation, and ATF3 with its downstream oxidative stress signals. In summary, the ATF3 pathway serves a vital role in the ovarian injury caused by PM2.5 exposures.
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic liver disease leading to inflammation with scaring and strictures of bile ducts, which can lead to liver cirrhosis. A subtype of PSC characterized by high serum IgG4 (sIgG4) levels has been reported to be associated with poor outcomes, but the exact role and the longitudinal development of sIgG4 levels in PSC progression remains to be clarified. The aim of this study was to investigate if subsequent analysis of sIgG4 levels allows the identification of the PSC phenotype with high sIgG4.
METHODS: sIgG4 values were repeatedly analysed in a well-characterized European PSC cohort of 110 individuals. Biochemical parameters, clinical endpoints, death and liver transplantation were compared between PSC subgroups.
RESULTS: 12.7% (n = 14) of PSC patients showed increased sIgG4 levels (PSC-IgG4). The values normalized in 57.1% (n = 8; PSC-IgG4norm) during follow-up measurements, whereas the values remained permanently elevated in 42.9% (n = 6; PSC-IgG4const). Serum values of AP and γGT were significantly higher in PSC-IgG4const compared to PSC-IgG4norm at final blood sampling. Furthermore, mean age at PSC diagnosis was markedly lower in PSC-IgG4const compared to PSC-IgG4norm.
CONCLUSIONS: This is the first study analyzing longitudinal development of sIgG4 in PSC. Our data indicate that only sequential determination of sIgG4 levels allow to accurately distinguish between the PSC phenotype with high sIgG4 and PSC with low sIgG4.
Carcinogenesis: Lifetime carcinogenicity bioassays were conducted in mice and rats. Mice were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day for 2 years. There was an increased incidence of Harderian gland adenomas in males and females in all treatment groups (starting at doses equivalent to 0.002 times the human 5 mg intravenous dose, based on body surface area, mg/m2). Rats were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day for 2 years. No increased incidence of tumors was observed at any dose (up to 0.1 times the human intravenous dose of 5 mg, based on body surface area, mg/m2).

  


Mutagenesis: Zoledronic acid was not genotoxic in the Ames bacterial mutagenicity assay, in the Chinese hamster ovary cell assay, or in the Chinese hamster gene mutation assay, with or without metabolic activation. Zoledronic acid was not genotoxic in the in vivo rat micronucleus assay. 

  


Impairment of Fertility: Female rats were given daily subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg beginning 15 days before mating and continuing through gestation. Inhibition of ovulation and a decrease in the number of pregnant rats were observed at 0.1 mg/kg/day (equivalent to the human 5 mg intravenous dose, based on AUC). An increase in preimplantation loss and a decrease in the number of implantations and live fetuses were observed at 0.03 and 1 mg/kg/day (0.3 to 1 times the human 5 mg human intravenous dose).
Participants will not receive any intervention during the first 6 months of the study. The participants will receive the study intervention at the end of 6 months, to ensure access to treatment for all participants.
Described is a graft animal model for propagating papillomavirus and for evaluating and testing candidate therapeutic agents against papillomavirus. The animal model comprises a recipient animal engrafted with injured skin graft infected with a host-specific papillomavirus (PV). The grafted skin, having demonstrable papillomas supports the propagation of its host-specific PV. Also described is a xenograft animal model for hosting and propagating human papillomavirus (HPV), thereby providing a means for generating infectious and passaging HPV suspensions, and for screening candidate therapeutic agents against HPV. In addition, a method for generating the xenograft human animal model is described also. The graph depicts single type HPV-11 wart induction in the cutaneous model by viral stock originally generated from sub-cutaneous xenograft warts. It demonstrates the high frequency of papilloma induction with single type HPV-11 in 2nd and 3rd generation using papillomavirus collected from serial xenograft passage.
Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
The present invention discloses a medicinal composition for curing cervical spondylosis and a preparation method of the composition. The medicinal composition is mainly prepared from incised notoptetygium rhizome or root, largeleaf gentian root, clematis root and kudzuvine root, and can also be added with hemlock parsley, red sage root, safflower, earthworm, saponaria vaccaria, ground beeltle, peach seed, marmor serpentinatum, olibanum and myrrh. The 14 raw medicinal materials can also be added with atractylodes rhizome, white peony alba, milkvetch root, phellodendron bark, rehmanniae, sea-ear shell and tangshen. The composition can be prepared into medicines in various preparation forms with conventional methods. The composition comprising 21 raw medicinal materials can be prepared with the following method: incised notoptetygium rhizome or root, hemlock parsley, atractylodes rhizome, olibanum and myrrh are added with water; the volatile oil is extracted and reserved; the rest 16 medicines are decocted with water, filtered, concentrated under reduced pressure, added with ethanol and left in a standing state; the ethanol is recovered, and the medicines are concentrated, prepared into granules, encapsulated or added with supplementary materials, and prepared into medicines in various preparation forms. When used for curing cervical spondylosis, the medicinal composition of the present invention has the functions of resisting inflammation, relieving pain, lowering the viscosity of blood plasma or increasing cerebral blood flow.
Vancomycin-resistant enterococci (VRE) occur in hospitalized patients, causing both infection and colonization. In recent years, there has been an increase in VRE in German and other hospitals, raising the question of how to control this epidemic best. To better understand the specific epidemiology and to guide infection control, we conducted a retrospective cohort study analyzing all patients with VRE at Hannover Medical School, a tertiary university clinic in Germany that specializes in solid organ transplantation. Epidemiologic and clinical characteristics of patients with VRE from 2015-2017 were collected. Basic epidemiologic parameters, including VRE incidence and incidence density, were calculated. Independent risk factors for nosocomial VRE infection compared to colonization were assessed using a logistic regression model. There were 1,492 VRE cases corresponding to 822 individual patients. The incidence was 0.8 VRE cases per 100 cases. A total of 536 (35.9%) of the 1,492 VRE cases were acquired nosocomially. Of the 1,492 cases, 912 cases had VRE-positive samples (894 Enterococcus (E.) faecium and 18 E. faecalis) in our hospital laboratory and the remaining cases were known VRE carriers. The vanB-phenotype was observed in 369 of the 894 (41.3%) E. faecium isolates and in 6 of the 18 (33.3%) E. faecalis isolates. There was an increase over time in the vanB-phenotype proportion in E. faecium (2015: 63 of 171, 36.8%, 2016: 115 of 322, 35.7% and 2017: 191 of 401, 47.6%). A total of 107 cases had a VRE infection (7.2% of all VRE cases) according to the criteria of the German National Reference Center for Surveillance of Nosocomial Infections. The remaining cases were only colonized. Among other factors, leukocytopenia (<1,000/μL), the use of a central venous catheter and the visceral surgery medical specialty were independently associated with nosocomial VRE infection. VRE imposed a relevant and increasing infection control burden at our hospital. Nosocomial VRE infection was predominantly found in certain medical specialties, such as hematology and oncology and visceral surgery. Infection control efforts should focus on these highly affected patient groups/specialties.
The method includes treating bone and joint diseases with a composition which includes collagen, essential minerals, and mineral lactate which were derived from the bones of crocodilos reptilia (crocodile). Crocodile collagen is made of a different ratio of amino acids than mammalian collagen which may be at least partly responsible for its therapeutic properties. The composition further includes a mixture of herbs. The mixture of herbs may include Clinacanthus nutans, Eclipta prostrata, Drynaria rhizome, and Auricularia polytricha. The herbs in the mixture of herbs each has one or more of the following properties: anti-inflammatory, analgesic, bone formation enhancement, and increases the number of osteoblast proliferation without impacting the number or activity of osteoclasts. The composition may also include essential minerals which are important for bone formation. This composition may be useful to treat or prevent several common bone or joint diseases including osteoporosis, arthritis, and osteogenesis imperfecta.
Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
The present invention relates to dendrobium stem health care tea and a preparing method thereof. Fresh dendrobium stem strips and leaves are used as raw materials and the dendrobium stem health care tea is obtained from preparation according to the following method: firstly, the fresh dendrobium stem strips are cut into pieces and are preheated in a preheater together with the dendrobium stem leaves with temperature of 38.5 DEG C to 39.5 DEG C and with time of 2 to 3 hours; after that kneading is carried out, the temperature is between 38 DEG C and 50 DEG C in the process of kneading, water in dendrobium stems is optimally not to be extruded out in the process of kneading, and kneading is not stopped until all the kneaded dendrobium stems are in the shapes of balls; then, the dendrobium stems for baked and shaped for 7 to 7 hours in an incubator with temperature of 38.5 DEG C to 39.5 DEG C, after shaped, the dendrobium stems are filled in a fruit grinding machine to be ground, polished and eliminated with dust, and the finished goods of the health care tea are obtained after the dendrobium stems are packed in a grading manner. The dendrobium stem health care tea prepared by the method of the present invention smells fragrant when people eat the dendrobium stem health care tea, people feel refreshing flavor which is not possessed by other kinds of common tea. After drunk, the tea can be eaten when people chew the tea, people feel thick, which is a characteristic that other kinds of tea do not have. The dendrobium stem health care tea has the advantages of moderate price and convenient eating. The present invention keeps the original drug ingredients of wild dendrobium stems, has the advantages of good medical effect, and strong health care function, and has advantages that other dendrobium stem products can not match with.
PURPOSE: The role of the nitric oxide synthases (NOSs) system in cerebral infarction has been examined in pharmacological studies with non-selective NOSs inhibitors. However, due to the non-specificity of the non-selective NOSs inhibitors, its role remains to be fully elucidated. We addressed this issue in mice in which neuronal, inducible, and endothelial NOS isoforms were completely disrupted.
METHODS AND RESULTS: We newly generated mice lacking all three NOSs by crossbreeding each single NOS-/- mouse. In the male, cerebral infarct size at 24 h after middle cerebral artery occlusion (MCAO) was significantly smaller in the triple n/i/eNOSs-/- genotype as compared with wild-type genotype. Neurological deficit score and mortality rate were also significantly lower in the triple n/i/eNOSs-/- than in the WT genotype. In contrast, in the female, there was no significant difference in the cerebral infarct size in the two genotypes. In the male triple n/i/eNOSs-/- genotype, orchiectomy significantly increased the cerebral infarct size, and in the orchiectomized male triple n/i/eNOSs-/- genotype, treatment with testosterone significantly reduced it. Cyclopaedic and quantitative comparisons of mRNA expression levels in cerebral infarct lesions between the male wild-type and triple n/i/eNOSs-/- genotypes at 1 h after MCAO revealed significant involvements of decreased oxidative stress and mitigated mitochondrial dysfunction in the alleviated cerebral infarction in the male triple n/i/eNOSs-/- genotype.
CONCLUSIONS: These results provide the first evidence that the NOSs system exerts a deleterious effect against acute ischemic brain injury in the male.
Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
PURPOSE: To lessen the dustiness of an impression material and to rapidly wet, disperse or dissolve the material by coating at least part of the dental impression material consisting of powdery alginate or its substitution with a coating material like xanthan rubber. CONSTITUTION: The dustiness of the dental impression material consisting of the powdery alginate or its substitution is suppressed. Namely, at least part of the impression material is coated with the coating material, such as xanthan rubber, hydroxyethyl or hydroxymethyl cellulose. The coating material easily and rapidly wets, disperses or dissolves at the time of forming the solidifiable impression material paste from the powdery impression material by mixing the coating material with water or substitutive liquid. Consequently, the impression material coated with the coating material has the lessened dustiness and rapidly wets, disperses or dissolves. The coating material is preferably used at 1 to 10 wt.% of the total weight of the powdery impression material.
Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
Calcium chlortetracycline is prepared by treating an aqueous slurry of amorphous chlortetracycline with continuous additions of calcium hydroxide to a pH not above 9.5, diluting with water and filtering. The separated filter cake is slurried with water and then passed through a comminuting mill.  After dilution with water, calcium hydroxide is added to pH 8.5, the slurry allowed to stand and filtered to recover the calcium chlortetracycline. Calcium tetracycline is prepared in a similar manner.ALSO:A sprayable composition, for use from a pressurized container comprises amorphous calcium tetracycline or calcium chlortetracycline of particle size less than about 15 microns in liquid haloalkane of specific gravity not less than 1.37 and a vapour pressure at 25 DEG  C. between 12 and 100 lbs. per sq. inch.  A local anaesthetic may also be incorporated. In filling a container, the tetracycline material may be admixed with a haloalkane which can be handled directly under room conditions, the mixture filled into the container and a more volatile haloalkane added under refrigerated conditions before sealing. Examples of compositions for treating pink eye in cattle and skin lesions and eye affections are given.
The invention discloses a gene III type avian reovirus variant strain and application thereof in preparing vaccines. The invention successfully separates 1 strain of gene III type avian reovirus variant from joint tissues of examined sick chickens, which is named ARV-HLJ21-1690401 and is preserved in China general microbiological culture collection center (CGMCC) No.45563. The result of the sigma C genetic evolution analysis shows that the variant strain is positioned on the III-type branch of the ARV gene. The variant has obvious pathogenicity to chicken embryo and SPF chicken, and can cause 90% death of inoculated chicken embryo and 100% morbidity of inoculated SPF chicken of 6 weeks old. The vaccine can be prepared into inactivated vaccine, and the immune SPF chicken can induce to generate better antibody level and can provide complete immune protection for the isotypic strains. The invention provides a new technical means for preventing the avian reovirus disease.